Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Buys $30,007.86 in Stock

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) insider Barbara White purchased 4,638 shares of the stock in a transaction dated Thursday, March 14th. The stock was purchased at an average price of $6.47 per share, for a total transaction of $30,007.86. Following the completion of the acquisition, the insider now directly owns 184,159 shares in the company, valued at approximately $1,191,508.73. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Corbus Pharmaceuticals stock traded down $0.13 during midday trading on Friday, hitting $6.70. The company had a trading volume of 2,511,363 shares, compared to its average volume of 1,726,470. The firm has a market capitalization of $431.45 million, a P/E ratio of -6.84 and a beta of 2.17. Corbus Pharmaceuticals Holdings Inc has a 12-month low of $4.50 and a 12-month high of $9.11.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.30) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.07). The company had revenue of $1.93 million during the quarter, compared to analysts’ expectations of $1.99 million. Corbus Pharmaceuticals had a negative net margin of 1,154.52% and a negative return on equity of 101.91%. As a group, analysts anticipate that Corbus Pharmaceuticals Holdings Inc will post -0.91 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. Alps Advisors Inc. raised its position in shares of Corbus Pharmaceuticals by 30.7% in the 4th quarter. Alps Advisors Inc. now owns 132,272 shares of the biopharmaceutical company’s stock valued at $772,000 after purchasing an additional 31,040 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Corbus Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after purchasing an additional 11,609 shares during the last quarter. IFP Advisors Inc raised its position in shares of Corbus Pharmaceuticals by 6.8% in the 4th quarter. IFP Advisors Inc now owns 1,608,569 shares of the biopharmaceutical company’s stock valued at $9,458,000 after purchasing an additional 102,323 shares during the last quarter. D.A. Davidson & CO. raised its position in shares of Corbus Pharmaceuticals by 76.5% in the 4th quarter. D.A. Davidson & CO. now owns 36,460 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 15,800 shares during the last quarter. Finally, Vanguard Group Inc raised its position in shares of Corbus Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc now owns 2,390,014 shares of the biopharmaceutical company’s stock valued at $18,045,000 after purchasing an additional 11,609 shares during the last quarter. 45.31% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $38.00 price target (up from $36.00) on shares of Corbus Pharmaceuticals in a report on Friday, January 11th. ValuEngine upgraded shares of Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st. HC Wainwright restated a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals in a report on Friday, January 4th. Zacks Investment Research upgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.50 price target on the stock in a report on Thursday. Finally, Royal Bank of Canada assumed coverage on shares of Corbus Pharmaceuticals in a report on Friday, December 7th. They issued an “outperform” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Corbus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $22.90.

COPYRIGHT VIOLATION WARNING: “Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Buys $30,007.86 in Stock” was reported by Modern Readers and is the sole property of of Modern Readers. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.modernreaders.com/news/2019/03/17/corbus-pharmaceuticals-holdings-inc-crbp-insider-buys-30007-86-in-stock.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.

Read More: Cash Flow

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.